Aquestive Therapeutics IncNASDAQ:AQST
- LAST PRICE3.1850
- TODAY'S CHANGE (%)-0.0950 (-2.8963%)
- Bid / Lots3.1800/ 5
- Ask / Lots3.1900/ 14
- Open / Previous Close3.2700 / 3.2800
- Day Range
- 52 Week Range
- Volume341,117
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AQST |
|---|---|---|
| 09:32 ET | 15203 | 3.295 |
| 09:34 ET | 500 | 3.295 |
| 09:36 ET | 2919 | 3.26 |
| 09:38 ET | 3295 | 3.28 |
| 09:39 ET | 300 | 3.28 |
| 09:41 ET | 899 | 3.28 |
| 09:43 ET | 633 | 3.28 |
| 09:45 ET | 300 | 3.275 |
| 09:48 ET | 13027 | 3.275 |
| 09:50 ET | 4568 | 3.275 |
| 09:52 ET | 1330 | 3.275 |
| 09:54 ET | 1023 | 3.29 |
| 09:56 ET | 200 | 3.29 |
| 09:57 ET | 13278 | 3.3 |
| 09:59 ET | 1410 | 3.31 |
| 10:01 ET | 5979 | 3.315 |
| 10:03 ET | 325 | 3.305 |
| 10:06 ET | 2143 | 3.3 |
| 10:08 ET | 1700 | 3.295 |
| 10:10 ET | 3000 | 3.27 |
| 10:12 ET | 1699 | 3.27 |
| 10:14 ET | 1100 | 3.26 |
| 10:15 ET | 100 | 3.26 |
| 10:17 ET | 1274 | 3.27 |
| 10:19 ET | 100 | 3.27 |
| 10:21 ET | 1400 | 3.27 |
| 10:26 ET | 4130 | 3.29 |
| 10:28 ET | 1825 | 3.3 |
| 10:30 ET | 200 | 3.295 |
| 10:32 ET | 3303 | 3.285 |
| 10:33 ET | 1976 | 3.283 |
| 10:35 ET | 400 | 3.285 |
| 10:37 ET | 1683 | 3.2899 |
| 10:39 ET | 700 | 3.265 |
| 10:42 ET | 700 | 3.26 |
| 10:44 ET | 200 | 3.27 |
| 10:48 ET | 1395 | 3.265 |
| 10:50 ET | 2799 | 3.26 |
| 10:51 ET | 2988 | 3.265 |
| 10:53 ET | 2775 | 3.26 |
| 10:55 ET | 2714 | 3.26 |
| 11:00 ET | 640 | 3.27 |
| 11:04 ET | 538 | 3.27 |
| 11:06 ET | 600 | 3.263 |
| 11:08 ET | 900 | 3.2603 |
| 11:09 ET | 3600 | 3.2685 |
| 11:11 ET | 1370 | 3.255 |
| 11:13 ET | 4211 | 3.25 |
| 11:15 ET | 15936 | 3.2439 |
| 11:18 ET | 12608 | 3.24 |
| 11:20 ET | 8000 | 3.24 |
| 11:22 ET | 2015 | 3.235 |
| 11:24 ET | 11522 | 3.22 |
| 11:26 ET | 1840 | 3.22 |
| 11:27 ET | 3030 | 3.22 |
| 11:29 ET | 4283 | 3.21 |
| 11:31 ET | 2348 | 3.21 |
| 11:33 ET | 1393 | 3.2002 |
| 11:36 ET | 1612 | 3.2 |
| 11:38 ET | 3202 | 3.2 |
| 11:40 ET | 35582 | 3.21 |
| 11:42 ET | 1812 | 3.2 |
| 11:44 ET | 12195 | 3.19 |
| 11:45 ET | 5746 | 3.1801 |
| 11:47 ET | 2490 | 3.18 |
| 11:49 ET | 2847 | 3.175 |
| 11:51 ET | 1713 | 3.17 |
| 11:54 ET | 4590 | 3.18 |
| 11:56 ET | 200 | 3.18 |
| 11:58 ET | 9706 | 3.19 |
| 12:00 ET | 1200 | 3.195 |
| 12:03 ET | 2174 | 3.19 |
| 12:05 ET | 2924 | 3.195 |
| 12:07 ET | 5300 | 3.1988 |
| 12:09 ET | 525 | 3.19 |
| 12:12 ET | 2617 | 3.19 |
| 12:14 ET | 5914 | 3.19 |
| 12:16 ET | 1190 | 3.195 |
| 12:18 ET | 3647 | 3.195 |
| 12:20 ET | 2400 | 3.1992 |
| 12:21 ET | 2150 | 3.195 |
| 12:23 ET | 591 | 3.19 |
| 12:25 ET | 23340 | 3.185 |
May 10, 2024
DJ Aquestive Therapeutics Initiated at Outperform by Leerink Partners, from 3:09PM ET on Friday May 10, 2024 by Dow Jones
3:09PM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference, from 8:00AM ET on Thursday May 09, 2024 by Dow Jones
8:00AM ET on Thursday May 09, 2024 by Dow JonesDJ Aquestive Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 7:32AM ET on Thursday May 09, 2024 by Dow Jones
7:32AM ET on Thursday May 09, 2024 by Dow Jones
May 7, 2024
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:19PM ET on Tuesday May 07, 2024 by Dow Jones
4:19PM ET on Tuesday May 07, 2024 by Dow Jones*DJ Aquestive Therapeutics 1Q Loss/Shr 17c >AQST, from 4:19PM ET on Tuesday May 07, 2024 by Dow Jones
4:19PM ET on Tuesday May 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aquestive Therapeutics Inc | 298.6M | -7.5x | --- |
Sanara Medtech Inc | 273.3M | -58.3x | --- |
Theravance Biopharma Inc | 466.2M | -11.1x | --- |
Dr Reddy's Laboratories Ltd | 11.7B | 17.1x | +24.18% |
OptiNose Inc | 186.8M | -4.6x | --- |
Daiichi Sankyo Co Ltd | 68.9B | 52.6x | --- |
Company Information
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Contact Information
- Headquarters
- 30 Technology DrWARREN, NJ, United States 07059-5166
- Phone
- 908-941-1900
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Santo Costa
- President, Chief Executive Officer, Director
- Daniel Barber
- Independent Vice Chairman of the Board
- John Cochran
- Chief Financial Officer, Senior Vice President
- A. Ernest Toth
- Chief Compliance Officer, Senior Vice President, General Counsel and Corporate Secretary
- Lori Braender
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $298.6M |
|---|---|
Revenue (TTM) | $51.5M |
Shares Outstanding | 91.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.82 |
EPS | $-0.43 |
Book Value | $-1.55 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | 5.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
